Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

Sponsor: Istanbul Medipol University Hospital
Collaborators: ScandiBio Therapeutics AB, Alanya Alaaddin Keykubat University, Sahlgrenska University Hospital, Sweden, KTH Royal Institute of Technology

Purpose

Establish metabolic improvements in AD and PD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, NR and serine. Concomitant use of pivotal metabolic cofactors via simultaneous dietary supplementation will stimulate to enhance hepatic ß-oxidation and this study's hypothesis is that this will result in increased mitochondrial activity in human brain cell-types.

Study Design

Randomized, double blind, placebo controlled, parallel assignment

Dose

Mixture of Serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.

Length of Intervention

Half dose given for 2 weeks (one dose taken after dinner), and full dose for 8 weeks (2 equal doses after breakfast and dinner)

Intrinsic Capacity

Cognition

Status

Recruiting

Condition or Disease 

Alzheimer Disease
Parkinson Disease

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Cognition, RecruitingANAD Staff